Mesenchymal Stem Cell Applications in Osteoporosis Treatment

Osteoporosis is characterised by a progressive loss of bone mass and microarchitectural deterioration, leading to increased fracture risk. Central to bone health is the balance between bone formation by osteoblasts and bone resorption by osteoclasts. Mesenchymal stem cells (MSCs) resident in the bone marrow can differentiate into osteoblasts, adipocytes or chondrocytes. In osteoporosis, a skewing of MSC differentiation towards adipogenesis at the expense of osteogenesis contributes to weakened skeletal integrity. Therapeutic strategies harness MSCs to restore this balance. Approaches include direct transplantation of autologous or allogeneic MSCs, genetic or pharmacological priming to enhance osteogenic potential, and delivery of MSC‐derived extracellular vesicles to convey pro‐regenerative signals. MSCs also exert immunomodulatory effects, dampening proinflammatory cytokines that drive osteoclast activation. Preclinical models demonstrate that MSC engraftment can increase bone mineral density, improve trabecular microstructure and reduce fracture incidence. Early clinical trials are under way to assess safety, optimal dosing and delivery routes. Challenges remain in ensuring efficient homing of MSCs to bone sites, prolonging cell survival, standardising manufacturing protocols and confirming long-term efficacy. With advances in scaffold engineering, gene editing and vesicle technology, MSC-based interventions hold promise as regenerative therapies that not only halt bone loss but also rebuild skeletal tissue in patients with osteoporosis.

Research from Nature Portfolio

Investigations into the intrinsic properties of mesenchymal progenitors across diverse osteoporotic models have revealed a conserved shift from osteoblastogenesis to adipogenesis. In models of age-related, hormonal and metabolic bone loss, bone marrow stromal cells displayed reduced colony forming efficiency and proliferation, alongside increased apoptosis and senescence markers. Osteogenic differentiation was broadly impaired, correlating with down-regulation of RUNX2, while expression of the adipogenic master regulator PPARγ was up-regulated. These findings highlight differential BMSC responses to distinct pathological stimuli, providing a theoretical framework for selectively modulating resident stem cells in regenerative therapies tailored to specific forms of osteoporosis.

Mesenchymal Stem Cell Applications in Osteoporosis Treatment publication trend

The graph below shows the total number of articles in mesenchymal stem cell applications in osteoporosis treatment across all publications each year (not limited to Nature Index journals).

Technical terms

Mesenchymal stem cell (MSC): A multipotent stromal cell capable of differentiating into bone, fat or cartilage lineages and exerting paracrine and immunomodulatory effects.

Osteoblastogenesis: The process by which precursor cells differentiate into osteoblasts, the bone-forming cells responsible for synthesising bone matrix and promoting mineralisation.

Adipogenesis: The differentiation of precursor cells into adipocytes, lipid‐laden cells whose excessive formation in bone marrow is associated with osteoporosis.

Extracellular vesicles: Nano-sized membranous particles released by cells that carry proteins, lipids and nucleic acids to mediate intercellular communication and tissue regeneration.

Homing: The capacity of transplanted or endogenous stem cells to migrate to and engraft within sites of injury or disease, such as osteoporotic bone.

Immunomodulation: The ability of MSCs to alter immune responses by secreting anti-inflammatory factors and regulating the activity of T cells, macrophages and other immune effectors.

References

1. Advancements in the pathogenesis of hepatic osteodystrophy and the potential therapeutic of mesenchymal stromal cells. Stem Cell Research & Therapy (2023).
2. Comparison of the therapeutic effects of mesenchymal stem cells derived from human dental pulp (DP), adipose tissue (AD), placental amniotic membrane (PM), and umbilical cord (UC) on postmenopausal osteoporosis. Frontiers in Pharmacology (2024).
3. Mesenchymal Stem Cells: Cell Fate Decision to Osteoblast or Adipocyte and Application in Osteoporosis Treatment. International Journal of Molecular Sciences (2018).
4. Advances in mesenchymal stem cell transplantation for the treatment of osteoporosis. Cell Proliferation (2020).
5. Mesenchymal progenitors in osteopenias of diverse pathologies: differential characteristics in the common shift from osteoblastogenesis to adipogenesis. Scientific Reports (2016).